Stonepine Capital Management’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-333,400
| Closed | -$3.69M | – | 83 |
|
|
2025
Q1 | $3.69M | Buy |
333,400
+9,076
| +3% | +$100K | 3.59% | 6 |
|
|
2024
Q4 | $3.45M | Buy |
324,324
+43,979
| +16% | +$468K | 2.79% | 13 |
|
|
2024
Q3 | $3.56M | Buy |
+280,345
| New | +$3.56M | 2.25% | 14 |
|
|
2023
Q3 | – | Sell |
-448,508
| Closed | -$4.64M | – | 26 |
|
|
2023
Q2 | $4.64M | Sell |
448,508
-253,027
| -36% | -$2.62M | 1.67% | 15 |
|
|
2023
Q1 | $6.48M | Sell |
701,535
-603,412
| -46% | -$5.58M | 2.17% | 12 |
|
|
2022
Q4 | $11.6M | Buy |
1,304,947
+180,727
| +16% | +$1.6M | 4.87% | 7 |
|
|
2022
Q3 | $9.35M | Buy |
1,124,220
+13,170
| +1% | +$110K | 4.21% | 7 |
|
|
2022
Q2 | $9.1M | Buy |
1,111,050
+842,217
| +313% | +$6.9M | 4.23% | 9 |
|
|
2022
Q1 | $2.34M | Buy |
+268,833
| New | +$2.34M | 0.97% | 20 |
|